In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinsons Disease

• Tipo: Artigo em Revista Científica Internacional
• Data: 2018

Autores

Lemos, A (Autor) Outra; Melo, R (Autor) Outra; Preto, AJ (Autor) Outra; Almeida, JG (Autor) Outra; Moreira, IS (Autor) Outra; Natalia N D S Cordeiro (Autor) FCUP

Revista

Título: Current Neuropharmacology

Vol. 16

Páginas: 786-848

ISSN: 1570-159X

Editora: Bentham Science

Indexação

ISI Web of Knowledge - 13 Citações

Scopus - 14 Citações

Outras Informações

ID Authenticus: P-00P-HZY

DOI: 10.2174/1570159x16666180308161642

Abstract (EN): Parkinson's Disease (PD) is a long-term neurodegenerative brain disorder that mainly affects the motor system. The causes are still unknown, and even though currently there is no cure, several therapeutic options are available to manage its symptoms. The development of novel anti-parkinsonian agents and an understanding of their proper and optimal use are, indeed, highly demanding. For the last decades, L-3,4-DihydrOxyPhenylAlanine or levodopa (L-DOPA) has been the gold-standard therapy for the symptomatic treatment of motor dysfunctions associated to PD. However, the development of dyskinesias and motor fluctuations (wearing-off and on-off phenomena) associated with long-term L-DOPA replacement therapy have limited its antiparkinsonian efficacy. The investigation for non-dopaminergic therapies has been largely explored as an attempt to counteract the motor side effects associated with dopamine replacement therapy. Being one of the largest cell membrane protein families, G-Protein-Coupled Receptors (GPCRs) have become a relevant target for drug discovery focused on a wide range of therapeutic areas, including Central Nervous System (CNS) diseases. The modulation of specific GPCRs potentially implicated in PD, excluding dopamine receptors, may provide promising non-dopaminergic therapeutic alternatives for symptomatic treatment of PD. In this review, we focused on the impact of specific GPCR subclasses, including dopamine receptors, adenosine receptors, muscarinic acetylcholine receptors, metabotropic glutamate receptors, and 5-hydroxytryptamine receptors, on the pathophysiology of PD and the importance of structure- and ligand-based in silico approaches for the development of small molecules to target these receptors.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 63